Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.51 |
| ▸ | IL1B | P01584 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197149 | 1.00 | CASP1 (0.51) | CASP1IL1BCTSLCTSKCTSS | |
| SCHEMBL13201994 | 0.93 | CTSK (0.43) | CASP1CTSLCTSKCTSSXIAP | |
| SCHEMBL14370033 | 0.90 | CASP1 (0.52) | CASP1IL1BXIAPBIRC3BIRC2 | |
| SCHEMBL950189 | 0.90 | CASP1 (0.52) | CASP1IL1BXIAPBIRC3BIRC2 | |
| SCHEMBL950190 | 0.90 | CASP1 (0.52) | CASP1IL1BXIAPBIRC3BIRC2 | |
| SCHEMBL12914620 | 0.90 | CASP1 (0.52) | CASP1IL1BXIAPBIRC3BIRC2 | |
| SCHEMBL14370034 | 0.86 | CASP1 (0.53) | CASP1IL1BCTSLCTSKCTSS | |
| SCHEMBL12450522 | 0.84 | CASP1 (0.46) | CASP1IL1BXIAPBIRC3BIRC2 | |
| Trifluoroacetic Acid SCHEMBL948891 | 0.82 | CASP1 (0.49) | CASP1CTSLCTSKCTSSCTSB | |
| Trifluoroacetic Acid SCHEMBL948894 | 0.82 | CASP1 (0.49) | CASP1CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP1 5/4885IL1B 1/4885CTSL 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.